Caryn Peterson, a director at Aspen Neuroscience, Inc., has reported her stock options in a recent SEC filing, which could have implications for the company's future and investor sentiment.

Aspen Neuroscience, Inc., identified under the SIC code 2834 for Pharmaceutical Preparations, is a company focused on developing innovative treatments in the life sciences sector. The company is publicly traded under the ticker symbol ASPE.

The filing, accession number 0001193125-26-439003, reveals that Peterson holds multiple stock options, including:

  • 27,011 shares at an exercise price of $3.96, expiring on June 30, 2031.
  • 10,119 shares at an exercise price of $7.71, expiring on June 15, 2032.
  • 19,226 shares at an exercise price of $5.74, expiring on November 25, 2035.

According to the filing, all options are fully vested and exercisable, which indicates a strong alignment between Peterson's interests and those of the company. This can be seen as a positive signal to investors regarding the company's leadership commitment.

The disclosure of stock options can affect various stakeholders, including current shareholders, potential investors, and competitors in the pharmaceutical preparations industry. It may influence how investors perceive the company's growth potential and management's confidence in its future.

The filing does not specify any upcoming actions or events related to this disclosure, leaving the future direction of Aspen Neuroscience open to speculation.